Pfizer picks Triana Biomedicines to find Molecular Glues for Cancer
US pharmaceutical giant Pfizer announced a groundbreaking collaboration with Triana Biomedicines to develop Molecular Glue Degraders. The partnership aims to create multiple advanced therapies, including cancer. The collaboration is seen as a significant step forward in developing advanced medical treatments that can address challenging disease targets.
Targeted protein degradation is a novel and fast-growing segment. TPD is predicted to reach half a billion by the end of 2024, with a tremendous increase of seven billion by 2035, at a 32% CAGR.
TPD small molecules, sometimes known as degraders, use the body’s cellular machinery to degrade certain proteins that lead to disease. Molecular glue degraders aid in linking together two molecules by attaching to a target protein and an E3-ligase enzyme. TPD allows the E3-ligase to tag the target protein for breakdown. Traditional small-molecule medicines often impede the function of target proteins, whereas molecular glues eliminate the proteins.
This new alliance demonstrates Pfizer’s focus on novel molecular glue degraders to meet unmet needs. Earlier in April 2024, Pfizer signed agreements with Arvinas and Ranok Therapeutics in November 2021.
TRIANA Biomedicines and Pfizer have formed a relationship to combine their scientific innovation expertise. TRIANA has established a solid reputation for its “target-first” molecular glue discovery platform, which employs cutting-edge technologies to find medicines for diseases that are difficult to target using standard drug techniques. With Pfizer’s extensive experience in drug development and large-scale clinical research, our collaboration has enormous potential for scientific advances.
Pfizer supports the relationship with an initial investment of USD 49 million, and TRIANA is eligible for milestone payments worth more than $1.5 billion if specific developmental and regulatory milestones are met. On top of these payments, TRIANA will receive tiered royalties based on future product sales generated by the agreement.
